With the Movember campaign gaining momentum, it’s an opportune time to address testicular cancer, a condition that disproportionately affects young men. Each year in Europe, over 25,000 new cases are diagnosed, making it the most prevalent cancer among this demographic. In the UK alone, there are approximately 50,000 survivors of testicular cancer, many of whom require ongoing monitoring after their initial diagnosis.
EDX Medical recognises the significance of raising awareness and applauds Movember’s role in educating the public about the disease and available treatments. As part of its commitment to improving diagnostic solutions, EDX Medical has partnered with the German biotech company mir|detect to distribute the innovative M371-Test in the UK and Nordic regions. This advanced blood test offers a reliable and cost-effective method to detect critical biomarkers of testicular cancer. It is particularly effective in identifying recurrences during follow-up monitoring, with a sensitivity rate of 100%.
The M371-Test sets a new standard in diagnostic precision and accuracy compared to traditional methods. Utilising a qPCR-based assay, it supports both the initial diagnosis and long-term monitoring of testicular germ cell tumours (TGCT). Its minimally invasive nature reduces the likelihood of over-treatment and potentially limits radiation exposure during follow-up. The test’s impressive performance is reflected in studies, showing a sensitivity of 90.1% and specificity of 94.0% for primary diagnosis, alongside 100% sensitivity and 96.3% specificity for recurrence monitoring. Moreover, the test is CE-marked under the In Vitro Diagnostic Regulation (EU) 2017/746, further affirming its clinical reliability.
These advancements are underpinned by robust scientific evidence. Recent studies, such as those by Belge et al. (2024) and Dieckmann et al. (2023, 2019), highlight the test’s role in transforming the detection and management of testicular cancer through the measurement of microRNA-371a-3p biomarkers. As research continues to validate its effectiveness, the M371-Test represents a critical step forward in improving outcomes for those affected by this disease.
The introduction of the M371-Test provides hope for faster and more accurate diagnoses, ensuring better long-term care for patients. With Movember as a backdrop, this innovation underscores the importance of leveraging cutting-edge science to address a critical health challenge.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
